Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression

The study is divided into 5 separate groups, Aim 1A, Aim 1B, Aim 2, Aim 3A and Aim 3B. Aims 1A and 1B will identify and evaluate patient-level factors that must be addressed in an intervention to increase hypertension medication adherence for (persons living with HIV) PWH who have achieved viral suppression. Aim 2 will identify HIV providers' practice norms after their patients achieve viral suppression and explore barriers faced in monitoring and managing patient adherence to antihypertensive medications to inform an intervention aimed at increasing antihypertensive medication adherence. Aim 3A will adapt the health care delivery intervention components to the Duke ID clinic context with key stakeholder input and data from Aims 1 and 2. Aim 3B will evaluate the feasibility and acceptability of the adapted health care delivery intervention to improve anti-hypertensive medication adherence and BP control in PWH at 24 weeks.

Inclusion criteria

Aims 1A and 1B

• Age ≥18 years
• Confirmed HIV+ diagnosis
• Undetectable HIV viral load: defined as the most recent HIV viral load <200 copies/mL checked within the past year (assessed via chart abstraction)
• Hypertension diagnosis in medical records
• Taking an antihypertensive medication
• Receiving care at the Duke HIV clinic

Aim 2

• HIV providers including infectious disease physicians, internists or advance practice practitioners who have a patient pool of PLWH under their care in the last 6 months.

Aim 3A

• Stakeholders composed of willing participants recruited from the Duke ID clinic and may include, HIV providers, clinic directors, nurses, pharmacists, social workers, people living with HIV who have hypertension and take antihypertensive medications, and representatives of the community advisory boards, and any other key stakeholders.

Aim 3 B

• Age ≥18 years
• Confirmed HIV+ diagnosis
• Receiving care at the Duke ID clinic
• Achievement of HIV suppression defined as having HIV-1 RNA <200 copies/ml
• Take antihypertensive medications
• Uncontrolled BP over a 12 months period defined by participants with systolic BP>130mmHg on ≥ 2 occasions in the past 12 months as indicated in the individual patient's electronic medical records

Exclusion criteria

Aims 1A, 1B and 3B

• Severely hearing or speech impaired, or other disability that would limit participation in the intervention components
• In a nursing home and/or receiving in-patient psychiatric care
• Terminal illness with life expectancy < 4 months
• No reliable access to a telephone
• Pregnant, breast-feeding, or planning a pregnancy during the study period
• Planning to move out of the area in the next 6 months
• Non-English speaking.